Saturday 17 October 2026
Export NVCT’s income statement to Excel — free account
Nuvectis Pharma, Inc.
NVCT Healthcare Biotechnology
In the quarter to June 2026, EPS was flat and free cash flow fell 34.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
18.48
0.45
−2.38%
Follow NVCT
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 3.08 | 7.14 | 4.44 | 5.33 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 20.92 | 18.65 | 12.10 | 11.52 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 8 | 11 | 13 | 13 | 13 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | 0 | (13) | (19) | (22) | (19) | (26) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | — | 0 | (13) | (19) | (22) | (19) | (26) | |||||
| Depreciation | — | — | — | — | — | — | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | 0.00 | (3.02) | (1.51) | (1.43) | (1.11) | (1.32) | |||||
| Cash flow | — | — | — | — | 0.00 | (2.23) | (1.07) | (1.03) | (0.72) | (0.73) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | 0.00 | (2.23) | (1.07) | (1.03) | (0.72) | (0.73) | |||||
| Book value | — | — | — | — | 0.00 | (2.58) | 1.12 | 0.78 | 0.57 | 0.84 | |||||
| Shares, m | — | — | — | — | 4 | 4 | 13 | 16 | 17 | 22 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (10) | (14) | (16) | (12) | (16) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | (10) | (14) | (16) | (12) | (16) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | 3 | 14 | 12 | 10 | 18 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | (6) | (20) | (19) | (19) | (32) | |||||
| Shareholders’ equity | — | — | — | — | 0 | (11) | 14 | 12 | 10 | 18 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (387.26) | (141.05) | (112.45) | (100.55) | (114.76) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | 0.18 | 233.98 | (1,188.73) | (168.51) | (173.41) | (205.30) | |||||
Negative figures in brackets.
Charts ten years each
Nuvectis Pharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PRME Prime Medicine, Inc. | $654.8M | — (loss-making) | — (loss-making) | +3.50% (above 0%: growing) | n/m | +4.40% (above 0%: growing) | 100.00% | (3,750.87%) | Compare |
| AVTX Avalo Therapeutics, Inc. | $644.1M | — (loss-making) | — (loss-making) | −70.14% (below 0%: shrinking) | n/m | +75.70% (above 0%: growing) | 55.73% | 0.00% | Compare |
| WVE WAVE Life Sciences Ltd. | $628.6M | — (loss-making) | — (loss-making) | −73.88% (below 0%: shrinking) | n/m | −17.59% (below 0%: shrinking) | 100.00% | (3,248.33%) | Compare |
| CLYM Climb Bio, Inc. | $626.6M | — (loss-making) | — | — | n/m | +3.73% (above 0%: growing) | — | 0.00% | Compare |
| NVCT Nuvectis Pharma, Inc. | $618.0M | — (loss-making) | — | — | n/m | −34.57% (below 0%: shrinking) | — | 0.00% | |
| SLDB Solid Biosciences Inc. | $615.5M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −39.56% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ZVRA Zevra Therapeutics, Inc. | $609.9M | 10.5× | 10.5× | +53.25% (above 0%: growing) | −88.71% (below 0%: shrinking) | +670.87% (above 0%: growing) | 96.16% | 42.30% | Compare |
| PHAT Phathom Pharmaceuticals, Inc. | $606.8M | — (loss-making) | — (loss-making) | +88.02% (above 0%: growing) | n/m | +96.86% (above 0%: growing) | 79.68% | (5.34%) | Compare |
| OLMA Olema Pharmaceuticals, Inc. | $601.1M | — (loss-making) | — | — | n/m | −54.33% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $621.1M | — | — | −33.32% | — | +4.07% | 79.68% | 0.00% |
Nuvectis Pharma, Inc. (NVCT) key facts
- Nuvectis Pharma, Inc. (NVCT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, NVCT traded at $18.48, a market capitalization of $618.0 million.
- Return on equity was −205.3% and debt-to-equity 0.00.
Nuvectis Pharma, Inc. (NVCT) Latest News
No news at this impact. Lower the threshold for more.